Get the Stockscreener App
26.61
0.04%
-0.01
After Hours:
26.28
-0.33
-1.24%
Xencor Inc stock is traded at $26.61, with a volume of 919.60K.
It is down -0.04% in the last 24 hours and up +33.58% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
See More
Previous Close:
$26.62
Open:
$26.05
24h Volume:
919.60K
Relative Volume:
0.82
Market Cap:
$1.98B
Revenue:
$97.36M
Net Income/Loss:
$-172.42M
P/E Ratio:
-11.58
EPS:
-2.2984
Net Cash Flow:
$-188.84M
1W Performance:
+2.11%
1M Performance:
+33.58%
6M Performance:
+108.87%
1Y Performance:
+217.92%
1-Day Range:
$25.40
$26.76
1-Week Range:
$25.40
$28.98
52-Week Range:
$8.19
$30.61
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
26.61 | 2.01B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
The Manufacturers Life Insurance Company Buys Shares of 49,696 Xencor, Inc. $XNCR - MarketBeat
XNCR stock holds steady as Xencor eyes next trial milestones - AD HOC NEWS
Seven Fleet Capital Management LP Has $5.93 Million Stake in Xencor, Inc. $XNCR - MarketBeat
Man Group plc Takes Position in Xencor, Inc. $XNCR - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR - MarketBeat
XNCR Maintained by JP Morgan -- Price Target Raised to $21.00 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock - MarketBeat
Technical Reactions to XNCR Trends in Macro Strategies - Stock Traders Daily
Xencor to Present at the 2026 Cantor Global Healthcare Conference - BioSpace
Xencor (XNCR) Maintained by Raymond James -- Price Target Raised to $46 - GuruFocus
Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating - marketscreener.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Xencor (NASDAQ:XNCR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Hsbc Holdings PLC Buys Shares of 125,482 Xencor, Inc. $XNCR - MarketBeat
Legal & General Group Plc Acquires Shares of 1,091,177 Xencor, Inc. $XNCR - MarketBeat
Deutsche Bank AG Acquires New Shares in Xencor, Inc. $XNCR - MarketBeat
Bank of America Corp DE Sells 263,315 Shares of Xencor, Inc. $XNCR - MarketBeat
BlackRock Inc. Buys Shares of 13,651,261 Xencor, Inc. $XNCR - MarketBeat
Xencor (NASDAQ:XNCR) Stock Price Down 9%What's Next? - MarketBeat
368,305 Shares in Xencor, Inc. $XNCR Bought by Seven Fleet Capital Management LP - MarketBeat
ADAR1 Capital Management LLC Invests $3.74 Million in Xencor, Inc. $XNCR - MarketBeat
Primecap Management Co. CA Invests $163.92 Million in Xencor, Inc. $XNCR - MarketBeat
Xencor (NASDAQ:XNCR) Reaches New 52-Week HighHere's Why - MarketBeat
Xencor (XNCR) Session: Rises 2.96% to $27.80 in the Latest Reading; Price Setup: the Price Remains Bounded by the Supplied Support and Resistance on the DayVolume Profile - vinanet.vn
103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC - MarketBeat
Xencor stock hits 52-week high at 26.18 USD - Investing.com
Xencor stock hits 52-week high at 26.18 USD By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $20 to $44 - Moomoo
Xencor (NASDAQ:XNCR) Hits A Fresh High: What Comes Next? - Kalkine Media
Xencor (NASDAQ:XNCR) Sets New 52-Week HighShould You Buy? - MarketBeat
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline? - simplywall.st
Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR - MarketBeat
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts - simplywall.st
Analysts' Revenue Estimates For Xencor, Inc. (NASDAQ:XNCR) Are Surging Higher - Moomoo
(XNCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Xencor (NASDAQ:XNCR) Hits New 1-Year HighHere's What Happened - MarketBeat
XNCR Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.89% Share UptickFree Cash Flow Trends - vinanet.vn
Xencor stock hits 52-week high at 21.99 USD By Investing.com - Investing.com Canada
Xencor stock hits 52-week high at 21.99 USD - Investing.com
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results - webull.com
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit - Yahoo Finance
BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $20 - Moomoo
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Xencor Inc (XNCR) Stock News Today - TradingKey
Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside - TradingView
Xencor, Inc. (XNCR) Stock Report: A Biotech Innovator With 40.83% Upside Potential - DirectorsTalk Interviews
Barclays Reaffirms Their Buy Rating on Xencor (XNCR) - theglobeandmail.com
Xencor: Q2 Earnings Snapshot - AOL.com
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $44 - Moomoo
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):